AZD0120, a rapidly manufactured CAR T product, was used successfully in a small number of patients with multiple myeloma with ...

Confirmed responses deepened with an average maximum tumor reduction from baseline of 89% and median time on treatment ...

AUCATZYL® (obecabtagene autoleucel) net product revenue of $23.3 million* for the fourth quarter of 2025 and $74.3 million* for the full year of ...

Dr. Miranda Gogishvili, a medical oncologist at the High Technology Medical Center, University Clinic in Tbilisi, Georgia, ...

More than half of patients with recurrent/advanced disease were progression-free at 6 mont ...

Targeted maintenance therapy with gilteritinib (Xospata; Astellas) following allogeneic hematopoietic stem cell ...

Gotistobart reduced risk of death by 54% and doubled 12-month survival vs chemotherapy in advanced squamous NSCLC after prior ...

Tickets are going fast for this year’s St. Jude Dream Home Giveaway. KKTV was honored to visit St. Jude Children’s Research ...

What is the best way to handle cellphones in schools? That’s a question Michigan educators are grappling with this spring ...

CAR T-cell therapy is a one-time intensive treatment that could potentially lead to a long remission, where Tec-Dara is an ...

SCLC, addressing a high-relapse setting with limited second-line efficacy and modest survival benefit. Ifinatamab deruxtecan ...